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Abstract
 
Aims
 
The long-term efficacy of epalrestat, an aldose reductase inhibitor, in improving subjective symptoms and nerve
function was comprehensively assessed to identify patients with diabetic peripheral neuropathy who responded to epal-
restat treatment.
 
Methods
 
Stratified analyses were conducted on data from patients in the Aldose Reductase Inhibitor—Diabetes Com-
plications Trial (ADCT). The ADCT included patients with diabetic peripheral neuropathy, median motor nerve conduc-
tion velocity 
 
≥
 
 40 m/s and with glycated haemoglobin (HbA
 
1c
 
) 
 
≤
 
 9.0%. Longitudinal data on HbA
 
1c
 
 and subjective
symptoms of the patients for 3 years were analysed (epalrestat 
 
n
 
 
 
=
 
 231, control subjects 
 
n
 
 
 
=
 
 273). Stratified analyses
based on background variables (glycaemic control, grades of retinopathy or proteinuria) were performed to examine the
relationship between subjective symptoms and nerve function. Multiple logistic regression analyses were conducted.
 
Results
 
Stratified subgroup analyses revealed significantly better efficacy of epalrestat in patients with good glycaemic
control and less severe diabetic complications. In the control group, no improvement in nerve function was seen regardless
of whether symptomatic benefit was obtained. In the epalrestat group, nerve function deteriorated less or improved in
patients whose symptoms improved. The odds ratio of the efficacy of epalrestat vs. control subjects was approximately
2 : 1 (4 : 1 in patients with HbA
 
1c
 
 
 
≤
 
 7.0%).
 
Conclusion
 
Our results suggest that epalrestat, an aldose reductase inhibitor, will provide a clinically significant means
of preventing and treating diabetic neuropathy if used in appropriate patients.
Diabet. Med. 25, 818–825 (2008)
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Introduction
 
Various drugs have been developed to treat diabetic neuropathy
[1], including aldose reductase inhibitors (ARIs). ARIs suppress
the activity of aldose reductase, a rate-limiting enzyme involved
in the polyol pathway, which is enhanced in diabetic neuropathy.
The effects of ARIs on diabetic neuropathy and diabetes-related
complications have been investigated in animal and clinical
studies [2,3]. Clinical efficacy of ARIs in diabetic neuropathy
has been reported in terms of nerve function, subjective
symptoms and histopathological findings of neural tissue
[2–4]. Generally, parameters for nerve function, such as nerve
conduction velocity and vibration perception threshold (VPT)
are used as primary variables of efficacy of ARIs [5–9]. We
previously reported the results of the 3-year Aldose Reductase
Inhibitor—Diabetes Complications Trial (ADCT), which
demonstrated the clinical efficacy of epalrestat, an ARI, in
Japanese diabetic neuropathy patients with median motor
nerve conduction velocity (MNCV) as the primary endpoint
[10]. Stratified analyses of the ADCT data suggested that the
effects of epalrestat on median MNCV were most evident
in patients with better glycaemic control and without retino-
pathy or nephropathy [10].
Subjective symptoms may be more important to patients
than nerve function. In ADCT, the efficacy of epalrestat
was investigated by analysis of subjective symptoms such as
numbness of upper and lower extremities, sensory abnormalities
of lower extremities and cramp [10].
Here, we report additional analyses of ADCT data [10], in
which stratified analyses of subjective symptoms were performed
to identify patients likely to experience better responses to
epalrestat. We determined the correlation between amelioration
of subjective symptoms and nerve function to clarify the sig-
nificance of ARIs in the treatment of neuropathy. Furthermore,
we carried out logistic regression analysis using a compre-
hensive clinical assessment parameter based on nerve function
and subjective symptoms and performed quantitative analysis
of the efficacy of epalrestat adjusted for background variables.
 
Patients and methods
 
ADCT was conducted at 112 medical facilities in Japan between
1997 and 2003. The protocol was approved by the Institutional
Review Board of each medical facility and all patients gave
informed consent.
The ADCT methodology has been reported previously [10].
Patients had mild diabetic peripheral neuropathy based on
subjective symptoms, no foot ulcers and neurological dysfunc-
tion [at least two parameters: MNCV (indispensable) and VPT
or Achilles tendon reflex, etc.]. Patients were enrolled if they
had a median MNCV 
 
≥
 
  40  m/s (seemingly reversible) and
stable glycaemic control [glycated haemoglobin (HbA
 
1c
 
) 
 
≤
 
 9.0%,
with 
 
±
 
  0.5% variation in the previous 3  months]. Subjects
were excluded if the primary cause of the neurological disorder
was not diabetes (alcoholic neuropathy, carpal tunnel syndrome,
sequelae of cerebrovascular disease, etc.), if they had peripheral
arterial disease (ankle brachial pressure index of 
 
≤
 
 0.8) or
severe hepatic or renal disorder, if they were participating in
other interventional studies, or if they were receiving other
experimental medications for diabetic neuropathy, prostaglandin
E
 
1
 
 preparations or any other medication that affects symptoms
of diabetic neuropathy. Patients were randomized to either the
epalrestat or control groups; details of the randomization method
were described previously [10]. Epalrestat (50 mg) was admin-
istered orally three times daily before each meal (150 mg/day).
Both groups continued conventional therapy (diet treatment,
oral glucose-lowering agents, insulin and anti-hypertensive
agents). With the exception of rescue medication, new medica-
tion to aid neuropathy control was prohibited.
 
Study endpoints and measures of outcome
 
The primary endpoint was change from baseline to study end in
median MNCV in the patient’s non-dominant arm. This arm was
chosen to avoid any bias as a result of possible lower limb impair-
ment caused by the Japanese lifestyle (a tendency to sit straight).
Secondary endpoints included changes from baseline to study end
in minimum F-wave latency (MFWL) of the median motor nerve
and VPT. VPT was measured using a 128-Hz tuning fork by
measuring the time in seconds during which the patient felt
vibrations. Changes of subjective symptoms of diabetic neuropathy
were assessed using a 100-mm visual analogue scale (VAS).
For a general measure of symptoms, the mean score was calculated
for 10 symptoms (spontaneous pain in upper and lower extremities,
numbness of upper and lower extremities, paraesthesia or hyper-
aesthesia of lower extremities, dizziness, cramp, coldness, abnormal
sweating and constipation) and four symptoms in the lower ex-
tremities (spontaneous pain, numbness, paraesthesia or hyper-
aesthesia and cramp). The mean VAS of each symptom ranged
from 20 to 30. The symptom score using in this study is the mean
VAS of 10 symptoms per patient, although many values were
zero. The mean symptom score at the beginning of the study in
the control and epalrestat groups was 8.2 and 9.3, respectively.
The response to therapy was determined using a general
assessment of subjective symptoms and nerve function. Patients
were rated as responders if any of the following changes were
observed over the 3-year study period: 
 
≥
 
 1 m/s increase in median
MNCV [11], 
 
≥
 
 5% decrease in MFWL [12], 
 
≥
 
 50% increase of
time in VPT [13], or 
 
≥
 
 50% decrease in the mean score for 10
symptoms [14].
 
Statistical analysis
 
As for ADCT [10], efficacy analyses were performed in patients
who had data for at least 1 year, using the last-observation-
carried-forward (LOCF) method [15,16].
Statistical methods included 
 
χ
 
2
 
-tests for nominal scale,
Mann–Whitney 
 
U
 
-tests for ordered categorical scale, two-sample
 
t
 
-tests for comparison of mean values between groups and two-
way repeated 
 
ANOVA
 
 for changes in glycaemic control. Multiple
logistic regression analysis was conducted using the defined
parameters of efficacy. Normalization for the multiplicity of
stratified analyses was not performed. All analyses were carried
out using SAS Version 8.02 (SAS Institute, Cary, NC, USA).
 
P
 
 < 0.05 was considered statistically significant.
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Results
 
Patients
 
Patient clinical characteristics are provided in Table 1. There
were no significant differences between the two groups.
In ADCT [10], the control and epalrestat groups included
305 and 289 patients, respectively. Of these, 31 and 55
patients withdrew after < 1 year, respectively; the reasons for
withdrawal were a change in hospital (12 patients in each
group), co-morbid illnesses (seven in each group), amelioration
of symptoms (two epalrestat recipients), adverse events (20
epalrestat recipients), deterioration in symptoms (seven
control subjects) or other (five control subjects, 14 epalrestat
recipients). Both amelioration of symptoms and adverse events
were observed only in the epalrestat group, resulting in a
higher withdrawal rate in this group. Additionally, 59 and 53
patients had insufficient data for the primary efficacy analysis,
primarily because of the unavailability of an electromyogram
or a problem with the measuring technique. Thus, the primary
efficacy analysis included 215 and 181 patients in the control
and epalrestat groups, respectively.
This analysis included 273 patients in the control group and
231 patients in the epalrestat group, for whom data were available
on symptom change and glycaemic control. The correlation
between subjective symptoms and median MNCV was analysed
in 214 patients in the control group and 179 patients in the
epalrestat group.
 
Changes in glycaemic control
 
The changes in HbA
 
1c
 
 observed in the two treatment groups
are shown in Table 1. No significant differences between
epalrestat recipients and control subjects in glycaemic control
were observed at baseline or over 3 years of treatment.
 
Stratified subgroup analyses of symptoms
 
Stratified subgroup analyses were performed to examine the rela-
tionship between changes in symptom score for 10 symptoms
and glycaemic control, grade of retinopathy and grade of
proteinuria (Fig. 1).
In both groups, the mean symptom score improved
significantly from baseline at years 1, 2 and 3 (Fig. 1a). The
improvement was most evident in the epalrestat group and
differences between the two groups were significant at years 1,
2 and 3 (
 
P
 
 
 
=
 
 0.019, 
 
P
 
 
 
=
 
 0.002  and 
 
P
 
 
 
=
 
 0.009,  respectively;
Fig. 1a).
 
HbA
 
1c
 
In patients with HbA
 
1c
 
  <  7.0%, the mean symptom score
improved significantly in both groups at year 1, 2 and 3. The
improvement was most evident with epalrestat and significant
between-group differences were observed at years  1 and 2
(
 
P
 
 
 
=
 
 0.042  and 
 
P
 
 
 
=
 
  0.049, respectively). In patients with
HbA
 
1c
 
 
 
≥
 
 7.0% and < 9.0%, the control group showed signifi-
cant improvement in the mean symptom score at year  1,
whereas epalrestat recipients showed significant improvement
at years 1, 2 and 3. Improvements in the mean symptom score
were significantly greater with epalrestat than control at
years  2 and 3 (
 
P
 
 
 
=
 
 0.009  and 
 
P 
 
=
 
 0.027,  respectively).  In
patients with HbA
 
1c
 
 
 
≥
 
 9.0%, the control group showed no
significant improvement in the mean symptom score at any
time points, whereas the epalrestat group showed significant
improvement at years 2 and 3. There were no significant
between-group differences at any time points (Fig. 1a).
Patient characteristics Control (n = 273) Epalrestat (n = 231) P-value
Sex
Male 161 (59.0) 132 (57.1)
Female 112 (41.0) 99 (42.9) 0.678*
Age (years) 61.5 ± 9.0 61.0 ± 10.0 0.541†
Duration of diabetes (years) 12.5 ± 8.0 13.2 ± 9.1 0.408†
Duration of neuropathy (years) 3.3 ± 3.6 3.7 ± 4.9 0.363†
HbA1c
HbA1c before and after treatment
0 years 7.0 ± 0.1 7.2 ± 0.1
3 years 7.2 ± 0.1 7.3 ± 0.1 0.122‡
Change over 3 years
< 7.0% 71 (26.0) 51 (22.1)
7.0% ≤ HbA1c < 9.0% 156 (57.1) 141 (61.0) 0.470§
≥ 9.0% 46 (16.8) 39 (16.9)
Data are means ± standard deviation (SD) or n (%).
P-values were calculated using *χ2- tests, †two-sample t-test, ‡ANOVA and §Mann–Whitney 
U-test. Duration of neuropathy refers to the mean patient-reported duration of neuropathy 
symptoms.
HbA1c, glycated haemoglobin.
Table 1 Patient characteristics at baseline
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Grade of retinopathy
 
In patients with no or background retinopathy at baseline, the
mean symptom score improved significantly in both groups at
years 1, 2 and 3. The improvement was significantly greater in
the epalrestat group at years 1, 2 and 3 (
 
P
 
 
 
=
 
 0.002, 
 
P
 
 < 0.001
and 
 
P
 
 < 0.001, respectively). In patients with pre-proliferative
or proliferative retinopathy, the control group showed significant
improvement only at year 1, whereas the epalrestat group
FIGURE 1 Effects of epalrestat on symptom 
score according to glycated haemoglobin 
(HbA1c) over 3 years (a), baseline level of 
retinopathy (b) and baseline level of proteinuria 
(c).  , epalrestat group;  , control group. Data 
are reported as means ± standard error (SE). 
P-values were calculated using the two-sample 
t-test. *P < 0.050, **P < 0.010 and 
***P < 0.001 were calculated vs. baseline using 
the paired t-test. P-values are stated for 
between-group differences.
 
dme_2490.fm  Page 821  Wednesday, June 18, 2008  7:59 PM 
DIABETIC
 
Medicine Appropriate target patients for ARI treatment • 
 
N. Hotta et al.
 
© 2008 The Authors.
 
822
 
Journal compilation © 2008 Diabetes UK. 
 
Diabetic Medicine
 
, 
 
25
 
, 818–825
 
showed significant improvement at years 1 and 2; there were
no significant between-group differences at any time points
(Fig. 1b).
 
Grade of proteinuria
 
In patients with no proteinuria at baseline, the mean symptom
score improved significantly in both groups at years 1, 2 and 3.
The improvement was significantly greater with epalrestat at
years  2 and 3 (
 
P
 
 
 
=
 
 0.010  and 
 
P
 
 
 
=
 
  0.038, respectively). In
patients who had microalbuminuria or clinical albuminuria at
baseline, the epalrestat group showed significant improvement
of the mean symptom score at years  1, 2 and 3, but the
between-group differences were not statistically significant at
any time points (Fig. 1c). The same trend was observed for
four symptoms of the lower extremities (data not shown).
 
Correlation between subjective symptoms and median MNCV
 
Figure  2 shows changes from baseline in median MNCV
according to symptom amelioration at year 3. In patients
without improvement in the mean symptom score of 10 symp-
toms, deteriorations in median MNCV were –1.47 
 
±
 
 0.41 m/s
in the control group and –0.20 
 
±
 
 0.42 m/s in the epalrestat
group. Significantly less deterioration occurred in the epalre-
stat group (
 
P
 
 
 
=
 
 0.039). In patients with improvement in
the mean symptom score, median MNCV deteriorated by
–1.52 
 
±
 
  0.35  m/s in the control group and improved by
0.26 
 
±
 
 0.34 m/s in the epalrestat group. Despite amelioration
of symptoms, median MNCV deteriorated to a significantly
greater extent in the control group than in the epalrestat group
(
 
P
 
 < 0.001). Furthermore, in the control group, median MNCV
significantly deteriorated from baseline regardless of whether
patients achieved symptom amelioration. As shown in Fig. 2,
the same trend was observed for four symptoms of the lower
extremities.
 
Quantitative analysis of efficacy
 
The odds ratios (ORs) for achievement of a response to
epalrestat therapy, based on analysis of nerve function and
symptoms, are depicted in Fig.  3. In the multiple logistic
regression model (Model 1), which was adjusted for the
duration of diabetes mellitus, baseline HbA
 
1c
 
, HbA
 
1c
 
  over
3 years and grades of retinopathy and proteinuria, the OR for
achievement of a response to epalrestat therapy was 1.90
[95% confidence interval (CI) 1.32–2.75, 
 
P
 
 < 0.001].  For
Model 2, which was stratified by HbA
 
1c
 
 over 3 years, the
OR of achieving a response to epalrestat therapy was 3.68
(95% CI 1.61–8.43, 
 
P
 
 
 
=
 
 0.002) for patients with HbA
 
1c
 
 < 7.0%
and 1.65 (95% CI 1.03–2.64, 
 
P
 
 
 
=
 
  0.036) for those with
HbA
 
1c
 
 < 9.0%. In patients with HbA
 
1c
 
 
 
≥
 
 9.0%, the OR was
1.42; this value was not significant vs. the control group.
FIGURE 2 Amelioration of symptoms and change in median motor nerve conduction velocity (MNCV) after 3 years. Data are presented as mean ± SE. 
P-values were calculated vs. baseline using a two-sample t-test for inter-group comparisons and a paired t-test for intra-group comparisons. 
10 symptoms: spontaneous pain of upper and lower extremities, numbness of upper and lower extremities, leg paraesthesia or hyperaesthesia, dizziness, 
cramp, coldness, abnormal sweating, constipation; four leg symptoms: spontaneous pain, numbness, paraesthesia or hyperasthesia, cramp. 
***P < 0.001 vs. baseline. P-values are stated for between-group differences.
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Safety
In ADCT, 26 of 295 subjects (the epalrestat group, including
six patients of major protocol deviations) reported adverse
events (AEs; 8.8%); these occurred within the first year of
treatment in 22 of the 26 subjects. AEs included hepatic func-
tion abnormalities (seven cases), gastrointestinal symptoms
such as nausea and diarrhoea (eight cases), skin rash/eczema
(two cases) and one case each of vertigo, light-headedness,
dorsal pruritus, hot flushes, hand stiffness, weakness of a
lower extremity, oedema in a lower extremity, thirst and cere-
bral infarction. There were no severe AEs and no AEs were
thought to be directly related to the long-term administration
of epalrestat.
Discussion
As it is not expected that cure of diabetes mellitus will be
achieved, management of this condition focuses on maintain-
ing long-term glycaemic control and reducing the occurrence
and progression of diabetes-related complications, including
diabetic neuropathy. If diabetic neuropathy symptoms deteri-
orate or persist, they can cause immeasurable mental and
physical stress to patients [17]; serious complications such as
ulcers or necrosis may culminate in amputation of an appendage
[18]. Diabetic neuropathy is often associated with considerable
mortality [19]. Therefore, it is of paramount importance to
diagnose diabetic neuropathy immediately and provide an
appropriate response to various risk factors [20,21] for the
development and progression of diabetic neuropathy.
The first priority in the treatment of diabetic neuropathy is
to maintain long-term glycaemic control. However, even when
strict glycaemic control is achieved via traditional treatments,
the occurrence and progression of diabetes-related complications
remain unavoidable [22]. One important metabolic factor
underlying diabetic neuropathy is an enhanced polyol pathway.
Suppression of this pathway may be an important treatment
strategy for diabetic neuropathy.
Diabetic neuropathy involves diverse symptoms such as
spontaneous pain and numbness. Patients often complain of
multiple symptoms. To determine distress in individual patients,
numerous studies have calculated scores for multiple symp-
toms [14,23,24]. In this study, we conducted stratified analyses
based on background variables, using the mean VAS score for
10 symptoms and the mean VAS score for four symptoms of
lower extremities, with the aim of identifying patients expected
to respond better to epalrestat therapy. The results indicated
that achievement of symptom amelioration differed significantly
between the epalrestat group and the control group for patients
with HbA1c  <  7.0% or <  9.0%, with no or background
retinopathy and no proteinuria. These results are consistent
with those from stratified analyses on median MNCV
FIGURE 3 Logistic regression analysis analysing the efficacy of epalrestat vs. control. Efficacy analysis was based on a defined index, in which patients 
satisfying at least one of the following requirements during a 3-year period were classified as responders to treatment and odds ratios (ORs) were 
calculated: 1, ≥ 1 m/s increase in median motor nerve conduction velocity (MNCV); 2, ≥ 5% decrease in F-wave latency; 3, ≥ 50% increase of time 
in vibration perception threshold (VPT); 4, ≥ 50% decrease in the mean score of 10 symptoms.
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reported previously [10] and provide evidence from both
aspects of nerve function and subjective symptoms that
epalrestat is more effective in patients with good glycaemic
control and limited complications.
Moreover, in our analyses, patients continuing conven-
tional therapy only (the control group) showed amelioration
of symptoms and changes in glycaemic control, but with
deterioration in median MNCV. This suggests that sup-
pression of neuropathy progression is difficult to achieve
with conventional therapy. In the epalrestat group, however,
less deterioration or improvement in median MNCV were
observed, regardless of whether patients achieved ameliora-
tion of symptoms. This suggests that epalrestat suppresses
the enhanced polyol pathway, which is one of the important
metabolic factors in the occurrence of diabetic neuropathy,
and provides a useful option for treatment of diabetic
neuropathy.
In diabetes mellitus, several reports have used multiple
logistic regression analysis to determine treatment efficacy
outcomes [25–27]. In this analysis, responders and non-
responders to treatment were defined based on a general
assessment of nerve function and subjective symptoms.
Quantitative analysis of the efficacy of epalrestat, after
adjustment for background variables, found that the OR was
approximately 2 : 1 for the efficacy of epalrestat vs. control
and 4 : 1 in patients with HbA1c < 7.0%. The results of our
comprehensive assessment of subjective symptoms and nerve
function show clinically significant benefit of epalrestat
treatment, particularly in patients with good glycaemic
control. Although the parameters used in this analysis are of
limited applicability, and careful interpretation is required,
these data are consistent with previous results from the
stratified analyses of median MNCV in ADCT [10], which
were quantitatively endorsed.
The existence of bias cannot be ruled out because of the
open-label trial design. However, measurement of nerve
function by the medical technologist and the assessment of the
electromyogram by the specialist physician were carried out
under blinded conditions and amelioration and/or deterioration
in subjective symptoms were correlated with changes in nerve
function in patients treated with epalrestat. Therefore, although
the overall design of this study may have some limitations, we
consider this bias to have been minimized.
Suppression of an enhanced polyol pathway, which has an
important role in the aetiology of diabetic neuropathy, cannot
be ignored. Therefore, in addition to improving glycaemic
control, treatment with ARIs is expected to play a significant
role in the management of diabetic neuropathy. This com-
prehensive study suggests that epalrestat, an ARI, provides
clinically significant benefit in preventing and treating diabetic
neuropathy if used in the appropriate patients.
Competing interests
None to declare.
Acknowledgements
The funder Ono Pharmaceutical Co. Ltd., Osaka Japan supplied
the sample drug, Kinedak tablets, which are a preparation of
Epalrestat.’ We are grateful to Dr Yasuo Akanuma (Institute
for Adult Diseases Asahi Life Foundation, Tokyo, Japan), Dr
Kempei Matsuoka (Saiseikai Shibuya Satellite Clinic, Tokyo,
Japan), Dr Yoshitomo Oka (Tohoku University Graduate School
of Medicine, Sendai, Japan), Dr Motoaki Shichiri (Research
Institute of Lifestyle-Related Diseases, Osaka, Japan), Dr
Takayoshi Toyota (Tohoku Rosai Hospital, Sendai, Japan),
Dr Mitsuyoshi Nakashima (Hamamatsu Institute of Clinical
Pharmacology and Therapeutics, Hamamatsu, Japan), Dr Isao
Yoshimura (Tokyo University of Science, Tokyo, Japan) and
Dr  Nobuo Sakamoto (Chubu Rosai Hospital, Nagoya,
Japan) for meaningful suggestions. We also thank doctors and
co-workers at the 112 medical facilities in Japan for provision
of clinical data.
References
1 Ziegler D. Treatment of neuropathic pain. In: Gries FA, Cameron NE,
Low PA, Ziegler D, eds. Textbook of Diabetic Neuropathy. Stuttgart:
Georg Thieme Verlag, 2003; 211–224.
2 Hotta N. New concepts and insights on pathogenesis and treatment
of diabetic complications: polyol pathway and its inhibition. Nagoya
J Med Sci 1997; 60: 89–100.
3 Oates PJ. Polyol pathway and diabetic peripheral neuropathy.
Int Rev Neurobiol 2002; 50: 325–392.
4 Feldman EL, Sullivan KA, Stevens MJ. Polyolpathway: aldose reduct-
ase inhibitors—hope for the future? In: Gries FA, Cameron NE, Low
PA, Ziegler D, eds. Textbook of Diabetic Neuropathy. Stuttgart:
Georg Thieme Verlag, 2003; 112–115.
5 Hotta N, Toyota T, Matsuoka K, Shigeta Y, Kikkawa R, Kaneko T
et al. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor,
for diabetic peripheral neuropathy: a 52-week multicenter placebo-
controlled double-blind parallel group study. Diabetes Care 2001;
24: 1776–1782.
6 Hotta N, Yasuda K, Sumita Y, Sano T, Kakuta H, Nagashima M
et al. Effects of a novel aldose reductase inhibitor, fidarestat (SNK-
860), on vibration perception threshold and subjective symptoms
in patients with diabetic polyneuropathy: An open-label pilot study.
Clin Drug Invest 2004; 24: 671–680.
7 Bril V, Buchanan RA, the AS-3201 Study Group. Aldose reductase
inhibition by AS-3201 in sural nerve from patients with diabetic
sensorimotor polyneuropathy. Diabetes Care 2004; 27: 2369–2375.
8 Bril V, Buchanan RA, the Ranirestat Study Group. Long-term effects
of ranirestat (AS-3201) on peripheral nerve function in patients with
diabetic sensorimotor polyneuropathy. Diabetes Care 2006; 29: 68–
72.
9 Greene DA, Arezzo JC, Brown MB. Effect of aldose reductase inhibi-
tion on nerve conduction and morphometry in diabetic neuropathy.
Zenarestat Study Group. Neurology 1999; 53: 580–591.
10 Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M
et al. Long-term clinical effects of epalrestat, an aldose reductase
inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter,
comparative Aldose Reductase Inhibitor-Diabetes Complications
Trial. Diabetes Care 2006; 29: 1538–1544.
11 Santiago JV, Snksen PH, Boulton AJ, Macleod A, Beg M, Bochenek W
et al. Withdrawal of the aldose reductase inhibitor tolrestat in
patients with diabetic neuropathy: effect on nerve function. J Diabetes
Complications 1993; 7: 170–178.
dme_2490.fm  Page 824  Wednesday, June 18, 2008  7:59 PMOriginal article DIABETICMedicine
© 2008 The Authors.
Journal compilation © 2008 Diabetes UK. Diabetic Medicine, 25, 818–825 825
12 Nakayama M, Nakamura J, Hamada Y, Chaya S, Mizubayashi R,
Yasuda Y et al. Aldose reductase inhibition ameliorates pupillary
light reflex and F-wave latency in patients with mild diabetic
neuropathy. Diabetes Care 2001; 24: 1093–1098.
13 Maser RE, Laudadio C, DeCherney GS. The effects of age and diabetes
mellitus on nerve function. J Am Geriatr Soc 1993; 41: 1202–1204.
14 Boulton AJ, Levin S, Comstock J. A multicentre trial of the aldose-
reductase inhibitor, tolrestat, in patients with symptomatic diabetic
neuropathy. Diabetologia 1990; 33: 431–437.
15 Gillings D, Koch G. The application of the principle of intention-
to-treat to the analysis of clinical trials. Drug Info J 1991; 25: 411–
424.
16 Department of Health and Human Services Food and Drug Admin-
istration. International conference on harmonisation; guidance on
statistical principles for clinical trials; availability—FDA. Notice. Fed
Regist 1998; 63: 49583–49598.
17 Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity,
and impact of painful diabetic peripheral neuropathy in type 2 diabetes.
Diabetes Care 2006; 29: 1518–1522.
18 Boulton AJM. Treatments for diabetic neuropathy. Curr Diab Rep
2001; 1: 127–132.
19 Vinik AI, Mehrabyan A. Diabetic neuropathies. Med Clin North Am
2004; 88: 947–999.
20 Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-
Tirgoviste C et al. Vascular risk factors and diabetic neuropathy.
N Engl J Med 2005; 352: 341–350.
21 Malik RA, Williamson S, Abbott C, Carrington AL, Iqbal J,
Schady W et al. Effect of angiotensin-converting enzyme (ACE)
inhibitor trandolapril on human diabetic neuropathy: randomised
double-blind controlled trial. Lancet 1998; 352: 1978–1981.
22 Diabetes Control and Complications Trial Research Group. The
effect of intensive treatment of diabetes on the development and
progression of long-term complications in insulin-dependent
diabetes mellitus. N Engl J Med 1993; 329: 977–986.
23 Bril V, Perkins BA. Validation of the Toronto Clinical Scoring System
for diabetic polyneuropathy. Diabetes Care 2002; 25: 2048–2052.
24 Dejgard A, Petersen P, Kastrup J. Mexiletine for treatment of chronic
painful diabetic neuropathy. Lancet 1988; 1: 9–11.
25 Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N,
Schrier RW. The effect of nisoldipine as compared with enalapril
on cardiovascular outcomes in patients with non-insulin-dependent
diabetes and hypertension. N Engl J Med 1998; 338: 645–652.
26 Thamer M, Ray NF, Taylor T. Association between antihypertensive
drug use and hypoglycemia: a case–control study of diabetic users of
insulin or sulfonylureas. Clin Ther 1999; 21: 1387–1400.
27 Inukai K, Watanabe M, Nakashima Y, Sawa T, Takata N, Tanaka M
et al. Efficacy of glimepiride in Japanese Type 2 diabetic subjects.
Diabetes Res Clin Pract 2005; 68: 250–257.
dme_2490.fm  Page 825  Wednesday, June 18, 2008  7:59 PM